Eli Lilly & Co. won't be needing pepper spray to fend off unwanted suitors. That's not because it lacks charm or offers few attractive assets, Bernstein analyst Tim Anderson says. A quirk in Indiana law protects the drugmaker from hostile takeovers.
The cost-effectiveness watchdogs in the U.K. really, really want people to take their clot-busting drugs. Days ago, the National Institute for Health and Care Excellence touted the benefits of anticoagulants for patients with atrial fibrillation, and now, they're considering new backing for Eli Lilly's Effient.
Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.
Eli Lilly and Boehringer Ingelheim say their in-development Lantus biosimilar proved as safe and effective as its reference treatment across 6 clinical trials.
Eli Lilly will hardly be the first in the field of GLP-1 treatments for diabetes if and when it launches dulaglutide, but the company believes its drug has the data to stand out among its rivals and claim the lion's share of a multibillion-dollar market.
Lilly has hit another setback in its effort to expand the market range for its key cancer drug ramucirumab, recently approved as Cyramza for stomach cancer.
The abstracts for the upcoming scientific conference of the ADA hit Friday, and top analyst Mark Schoenebaum at ISI flagged a critical issue for Eli Lilly's top drug candidate dulaglutide that could come back to haunt the troubled pharma giant after it reaches the market with its GLP-1 contender.
What's the best defense against all those fake versions of Viagra and other prescription erectile dysfunction pills that are sold online directly to men looking for a boost in the bedroom? Sanofi believes it has the answer: an over-the-counter version of Eli Lilly's ED blockbuster Cialis.
A clutch of Big Pharma companies is backing a competition to create predictive models that could lead to new targets for cancer drugs. Eli Lilly, Novartis and Pfizer are among the data funders of the competition, which calls for the development of models that show how essential a gene is to the survival of a cancer cell.
Boehringer Ingelheim has finally received some good news for its manufacturing facility in Ingelheim, Germany. The FDA has notified it that it has closed out a warning letter for the facility.